caa a22 4500 397591942 CHVBK 20180308164941.0 cr unu---uuuuu 161202e199604 xx s 000 0 eng 10.1093/jac/37.4.711 doi (NATIONALLICENCE)oxford-10.1093/jac/37.4.711 In-vitro and in-vivo antibacterial activity of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum [Elektronische Daten] [Hye-Kyoung Song, Jeong-In Oh, Mu-Young Kim, Young-Zu Kim, In-Chull Kim, Jin-Hwan Kwak] LB10517 is a new injectable cephalosporin with a broad spectrum of antibacterial activity against Gram-opositive and Gram-negative bacteria. LB10517 inhibited 90% of methicillin-susceptible Staphylococcus aureus (MSSA) at 0.25 mg/L (MIC90), and was 8-fold more active than cefpirome. LB10517 was two- or four-fold more active than cefpirome against methicillin-susceptible Staphylococcus epidermidis (MSSE), Streptococcus pyogenes and Enterococcus faecalis. Both methicillin-resistant S. aureus (MRSA) and methicillin-resistant S. epidermidis (MRSE) were highly resistant to all compounds. LB10517 activity against most Enterobacteriaceae was comparable to or greater than that of cefpirome, and it also showed high activity against Pseudomonas aeruginosa. In a mouse septicaemia model, LB10517 exhibited excellent protective effects. In a respiratory tract infection model, the protective effect of LB10517 was comparable to that of cefpirome and ceftazidime. It was highly stable to hydrolysis by β-lactamases, showing better physiological efficiency for TEM-9 than the other test compounds. LB10517 had the most potent antibacterial activity against β-lactamase producing resistant strains. LB10517 did not induce β-lactamase production in Enterobacter cloacae 1194E. © 1996 The British Society for Antimicrobial Chemotherapy Original articles nationallicence Song Hye-Kyoung Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut Oh Jeong-In Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut Kim Mu-Young Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut Kim Young-Zu Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut Kim In-Chull Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut Kwak Jin-Hwan Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut Journal of Antimicrobial Chemotherapy Oxford University Press 37/4(1996-04), 711-726 0305-7453 37:4<711 1996 37 jac https://doi.org/10.1093/jac/37.4.711 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.4.711 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Song Hye-Kyoung Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut NATIONALLICENCE 700 1- Oh Jeong-In Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut NATIONALLICENCE 700 1- Kim Mu-Young Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut NATIONALLICENCE 700 1- Kim Young-Zu Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut NATIONALLICENCE 700 1- Kim In-Chull Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut NATIONALLICENCE 700 1- Kwak Jin-Hwan Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd., Tae-Jon 305-380, Korea aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/4(1996-04), 711-726 0305-7453 37:4<711 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford